Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Chronic myeloproliferative disorders (CMPD).

R Burkhardt, R Bartl, K Jäger

    Pathology, Research and Practice
    |November 1, 1984
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    The phageome in normal and inflamed human skin.

    Science advances·2023
    Same author

    Dietary fatty acids and endometrial cancer risk within the European Prospective Investigation into Cancer and Nutrition.

    BMC cancer·2023
    Same author

    [Hypernatremia and polyuria in a female patient with an initial diagnosis of secondary acute myeloid leukemia].

    Innere Medizin (Heidelberg, Germany)·2022
    Same author

    Risk of coronary stenosis after adjuvant radiotherapy for breast cancer.

    Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]·2022
    Same author

    Reducing bias and increasing surgical knowledge: multicentre prospective breast cancer studies.

    The British journal of surgery·2021
    Same author

    Risk of ischemic heart disease after radiotherapy for ductal carcinoma in situ.

    Breast cancer research and treatment·2018
    Same journal

    Autophagy modulation in ulcerative colitis with traditional Chinese medicine: A review.

    Pathology, research and practice·2026
    Same journal

    Ras signalling in infectious disease pathology: Mechanisms, tissue damage, and clinical implications.

    Pathology, research and practice·2026
    Same journal

    CBFβ-SMMHC in inv(16) AML: Fusion biology, RUNX1 dysregulation, and therapeutic targeting of a leukemogenic protein-protein interaction.

    Pathology, research and practice·2026
    Same journal

    Multifactorial pathophysiology of varicocele: Integrating hemodynamic, oxidative, and endocrine mechanisms.

    Pathology, research and practice·2026
    Same journal

    Comparative pathophysiology and pathology of transient ischemic attack, ischemic stroke, and reperfusion injury: Mechanistic and therapeutic perspectives.

    Pathology, research and practice·2026
    Same journal

    Taraxerol targets the HIF1A-NEK6 axis to block TDE-mediated M2 macrophage polarization and inhibits NSCLC progression.

    Pathology, research and practice·2026
    See all related articles

    Chronic myeloproliferative diseases (CMPD) are viewed as leukaemias of pluripotent stem cells. Different CMPD entities like PV, PT, and CML exhibit distinct prognoses based on predominant cell lines, with myelofibrosis and osteosclerosis as common end stages.

    Area of Science:

    • Hematology
    • Oncology
    • Stem Cell Biology

    Background:

    • Chronic myeloproliferative diseases (CMPD) present a wide clinical spectrum, understood as leukaemias originating from pluripotent stem cells.
    • Blastic transformation in CMPD represents a regression to a more primitive cellular differentiation state.
    • Classical CMPD entities like polycythemia vera (PV), thrombocythemia (PT), and chronic myeloid leukemia (CML) are characterized by their predominant proliferative cell lines and distinct prognoses.

    Purpose of the Study:

    • To review the pathogenic concepts and natural history of CMPD, emphasizing the role of stem cell leukaemias.
    • To analyze the clinical and histological features differentiating CMPD entities and their progression.
    • To investigate the etiologic factors and potential protective mechanisms in CMPD, particularly in relation to sex differences.

    Related Experiment Videos

    Main Methods:

    • Review of clinical, experimental, and histological evidence concerning CMPD.
    • Re-evaluation of bone marrow biopsies from untreated patients to assess diagnostic criteria.
    • Statistical analysis of patient data to identify correlations between sex, megakaryocyte morphology, and survival.

    Main Results:

    • Pure erythrocytic or megakaryocytic proliferations are more compatible with bone marrow function than granulocytic ones.
    • Combinations of granulocytic and megakaryocytic growth are associated with myelofibrosis/osteosclerosis (MF/OMS), potentially involving immune reactions and platelet factors.
    • Female patients with thrombocythemia show a higher prevalence of giant megakaryocytes and longer survival, suggesting a protective effect against abnormal platelet production.

    Conclusions:

    • CMPD can be conceptualized as leukaemias of pluripotent stem cells with varying clinical presentations and prognoses.
    • Histological classification reveals three major groups characterized by megakaryocyte morphology and distribution, with transitions observed between typical and atypical forms.
    • Blastic dedifferentiation and myelofibrosis represent common end stages in the natural history of CMPD, influenced by the specific proliferating cell lines.